

Axitinib is an investigational agent and has not been approved by regulatory agencies.

COMPOUND DESCRIPTION	Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3.
ABOUT VEGF RECEPTORS	<p>VEGF receptors are thought to play a role in the growth and spread of many tumors, including renal cell carcinoma, breast, lung, thyroid and colorectal cancer.¹</p> <p>VEGF receptors 1, 2 and 3 have potential roles in tumor growth, vascular angiogenesis, and metastatic progression of cancer (the spread of tumors).</p> <p>Preclinical evidence suggests that inhibiting all three VEGF receptor signaling pathways may more efficiently disrupt tumor growth, vascular angiogenesis, and metastatic progression of cancer through lymphangiogenesis than by inhibiting an individual pathway.</p>
CLINICAL STUDIES	<p>Axitinib is being studied as both a single agent and in combination with chemotherapy across several tumor types. The ongoing Phase 3 registration trial, AGILE 1032, (also known as the AXIS trial), is a randomized, open label efficacy and safety study of axitinib versus sorafenib in patients with previously treated metastatic renal cell carcinoma (mRCC).²</p> <p>Following is a list of some of the axitinib trials that are currently open and enrolling:</p> <p><u>mRCC</u></p> <p>Phase 3</p> <ul style="list-style-type: none"> • AGILE 1051 – Randomized, open-label efficacy and safety study of axitinib versus sorafenib in patients with metastatic renal cell carcinoma³ <p>Phase 2</p> <ul style="list-style-type: none"> • AGILE 1046 - Randomized, double-blind study of axitinib with or without dose titration in patients with metastatic renal cell carcinoma⁴

For more information, please visit www.pfizercancertrials.com or www.clinicaltrials.gov or call toll-free 1-877-369-9753 (in the United States and Canada) or +1-646-277-4066 (outside of the United States and Canada).

¹ Hicklin DJ, Ellis LM. Role of VEGF in Tumor Growth and Angiogenesis. *JCO*. 2007;23:1011-1027.

² ClinicalTrials.gov. Axitinib (Ag 013736) As Second Line Therapy for Metastatic Renal Cell Cancer. Available at: <http://www.clinicaltrials.gov/ct2/show/NCT00678392?term=axitinib&rank=1>. Accessed May 12th, 2010.

³ ClinicalTrials.gov. Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer. Available at: <http://www.clinicaltrials.gov/ct2/show/NCT00920816>. Accessed May 12th, 2010.

⁴ ClinicalTrials.gov. Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer. Available at: <http://www.clinicaltrials.gov/ct2/show/NCT00835978>. Accessed May 12th, 2010.